With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Funded by an unrestricted gift of $240,000 from Alumbra, a foundation established by philanthropist Christy Walton, the ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

South Korea is emerging as a key player in global pharmaceuticals, driven by an advanced healthcare ecosystem, strategic government initiatives, and ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

Leaders of the "Make America Healthy Again” movement cheered the ascent of Robert F. Kennedy Jr. to Health and Human Services ...

The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...